Literature DB >> 35182728

Site-specific mitochondrial dysfunction in neurodegeneration.

Anežka Vodičková1, Shon A Koren2, Andrew P Wojtovich3.   

Abstract

Mitochondria are essential for neuronal survival and mitochondrial dysfunction is a hallmark of neurodegeneration. The loss in mitochondrial energy production, oxidative stress, and changes in calcium handling are associated with neurodegenerative diseases; however, different sites and types of mitochondrial dysfunction are linked to distinct neuropathologies. Understanding the causal or correlative relationship between changes in mitochondria and neuropathology will lead to new therapeutic strategies. Here, we summarize the evidence of site-specific mitochondrial dysfunction and mitochondrial-related clinical trials for neurodegenerative diseases. We further discuss potential therapeutic approaches, such as mitochondrial transplantation, restoration of mitochondrial function, and pharmacological alleviation of mitochondrial dysfunction.
Copyright © 2019 Elsevier B.V. and Mitochondria Research Society. All rights reserved. All rights reserved.

Entities:  

Keywords:  Mitochondria-targeting therapeutics; Mitochondrial dysfunction; Neurodegeneration; Optogenetics; Transplantation

Mesh:

Substances:

Year:  2022        PMID: 35182728      PMCID: PMC9035127          DOI: 10.1016/j.mito.2022.02.004

Source DB:  PubMed          Journal:  Mitochondrion        ISSN: 1567-7249            Impact factor:   4.534


  290 in total

Review 1.  Unfolding the role of protein misfolding in neurodegenerative diseases.

Authors:  Claudio Soto
Journal:  Nat Rev Neurosci       Date:  2003-01       Impact factor: 34.870

Review 2.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

3.  A clinical trial of creatine in ALS.

Authors:  J M Shefner; M E Cudkowicz; D Schoenfeld; T Conrad; J Taft; M Chilton; L Urbinelli; M Qureshi; H Zhang; A Pestronk; J Caress; P Donofrio; E Sorenson; W Bradley; C Lomen-Hoerth; E Pioro; K Rezania; M Ross; R Pascuzzi; T Heiman-Patterson; R Tandan; H Mitsumoto; J Rothstein; T Smith-Palmer; D MacDonald; D Burke
Journal:  Neurology       Date:  2004-11-09       Impact factor: 9.910

4.  Selective targeting of an antioxidant to mitochondria.

Authors:  R A Smith; C M Porteous; C V Coulter; M P Murphy
Journal:  Eur J Biochem       Date:  1999-08

Review 5.  Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease.

Authors:  D Allan Butterfield; Tanea Reed; Rukhsana Sultana
Journal:  Free Radic Res       Date:  2010-10-13

6.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 7.  Normal huntingtin function: an alternative approach to Huntington's disease.

Authors:  Elena Cattaneo; Chiara Zuccato; Marzia Tartari
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870

8.  The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.

Authors:  Anne-Laure Mahul-Mellier; Johannes Burtscher; Niran Maharjan; Laura Weerens; Marie Croisier; Fabien Kuttler; Marion Leleu; Graham W Knott; Hilal A Lashuel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-19       Impact factor: 11.205

9.  A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.

Authors:  W Reid Thompson; Brittany Hornby; Ryan Manuel; Elena Bradley; Janice Laux; Jim Carr; Hilary J Vernon
Journal:  Genet Med       Date:  2020-10-20       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.